Company intelligence / Profile preview
EveryONE Medicines
Boston, Massachusetts, United Stateseomeds.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
EveryONE Medicines is pioneering a system to deliver individualized antisense oligonucleotide therapies tailored to the unique genetic mutations of children with life-threatening neurodegenerative diseases. Inspired by the first n-of-one drug "milasen," the company aims to make such personalized treatments routine and accessible at scale. The company is building a proprietary AI-enabled platform and an expanding library of ASOs, but has not yet reported clinical trial results or commercialized products
- Therapeutic areas
- Neurology
- Modalities
- Antisense oligonucleotides (ASOs)Nucleic acid therapeutics
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on EveryONE Medicines.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EveryONE Medicines.